[HTML] frontiersin.org

[HTML][HTML] Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas

L Das, N Gupta, P Dutta, R Walia, K Vaiphei… - Frontiers in …, 2021 - frontiersin.org
Introduction Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal
multimodality therapy. The challenge lies in their early recognition and timely management …
被引用次数：10 相关文章

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas

L Das, N Gupta, P Dutta, R Walia… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Aggressive pituitary adenomas (APAs) are, by definition, resistant to optimal
multimodality therapy. The challenge lies in their early recognition and timely management …
[HTML] nih.gov

[HTML][HTML] Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas

L Das, N Gupta, P Dutta, R Walia, K Vaiphei… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Methods This was a single-center study of all patients with APAs who received at least 3
cycles of temozolomide (150–200 mg/m 2). Their baseline clinico-biochemical and …
[PDF] academia.edu

[PDF][PDF] Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas

L Das, N Gupta, P Dutta, R Walia, K Vaiphei… - Front. Endocrinol. 12 …, 2021 - academia.edu
Methods: This was a single-center study of all patients with APAs who received at least 3
cycles of temozolomide (150–200 mg/m2). Their baseline clinico-biochemical and …

Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.

L Das, N Gupta, P Dutta, R Walia, K Vaiphei… - Frontiers in …, 2021 - europepmc.org
Methods This was a single-center study of all patients with APAs who received at least 3
cycles of temozolomide (150-200 mg/m 2). Their baseline clinico-biochemical and …